Menu
Search
Home > Courses > Best of ACTHIV: Safety of Antiretroviral Therapy in Pregnancy

Best of ACTHIV: Safety of Antiretroviral Therapy in Pregnancy

Best of ACTHIV: Safety of Antiretroviral Therapy in Pregnancy
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Release Date: 9/15/2019
Review Date: 9/15/2019
Presenter
  • Lynne M. Mofenson, MD
    HIV Technical Advisor
    Elizabeth Glaser Pediatric AIDS Foundation
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Analyze the implications of timing of antiretroviral (ARV) exposure on birth defect risk
  2. Describe the results of the Botswana Tsepamo birth surveillance study related to preconception dolutegravir (DTG) use and neural tube defects (NTD) and what they mean for practice in the U.S.
  3. Appraise the importance of prospective reporting of antiretroviral drug exposure in pregnancy to the Antiretroviral Pregnancy Registry.
Presenter Bio
Lynne Mofenson, MD
Lynne M. Mofenson, MD is a pediatric infectious disease specialist who has spent her career doing research on prevention and treatment of pediatric and maternal HIV infection. In 2014, she retired from the U.S. National Institutes of Health after 26 years, where she led many of the key clinical trials on prevention of mother to child transmission and pediatric and maternal treatment. She currently serves as Senior HIV Technical Advisor to the Research Program at the Elizabeth Glaser Pediatric AIDS Foundation, where she is assisting in evaluating implementation of many of the interventions on treatment and prevention that she helped to design while at NIH.
Continuing Education Credit (The CE accreditation for this course has expired - this section is only for your information)

The enduring material is jointly provided by Beaumont Health, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 13th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 11-13, 2019 in Miami, FL. The Conference was supported by the Clinical Education Initiative, New York State Department of Health, AIDS Institute. The conference and this web archive were supported by educational grants from Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co., and ViiV HealthCare.

 

Hardware/Software Requirements To access this activity hardware and software requirements are noted below.

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later
Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection • Flash: Adobe Flash Player 9 or later

Copyright 2019. American Academy of CME, Inc., Beaumont Health, and American Conference for the Treatment of HIV.

Resources: